Nilaya Varma, Co-Founder & Group CEO, Primus Partners, states that the proposed US tariffs on pharmaceutical imports should be viewed as a long-term strategic signal rather than an immediate disruption. He notes that Indian pharmaceutical companies should use this period to strengthen supply chain resilience, enhance manufacturing capabilities and diversify into complex generics, biosimilars and specialty drugs. He further highlights that establishing manufacturing facilities in the US is a time-intensive process requiring land acquisition, regulatory approvals and production validation, while cautioning that higher tariffs could increase medicine prices, disrupt the supply of affordable generic drugs and raise healthcare costs for patients and public health programmes in the United States.